# Mankind Pharma Limited (MANKIND)

> MANKIND closed at ₹2,492.80 on 30 Oct 2026, trailing P/E 45.5, market cap ₹1,02,953 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Mankind Pharma Limited (NSE: MANKIND) closed at ₹2,492.80 on 30 Oct 2026, +0.7% over one year, against a 52-week range of ₹1,909.70 – ₹2,642.00.

In the quarter ended 30 Sept 2026 (consolidated, filed 26 Oct 2026) it reported revenue of ₹4,338 cr and net profit of ₹711 cr, a 16.4% net margin; revenue grew 17.3% and profit grew 48.9% year on year.

On four consecutive filed quarters its trailing P/E is 45.5; since 21 May 2025 its own P/E has ranged from 39.2 to 56.5 (median 48.4), and today's reading is higher than 31% of those 357 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 16.2%, ROCE 17.9%, debt-to-equity 0.31, Piotroski F-score 8 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 62% of 63 sector peers; PBT margin higher than 62% of 63 sector peers; ROE higher than 65% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹2,492.80 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -0.3% / +9.9% / +0.7% |
| 52-week low – high | ₹1,909.70 – ₹2,642.00 |
| Market capitalisation | ₹1,02,953 cr |
| Trailing P/E | 45.5 |
| Price / book | 5.86 |
| EV / EBITDA | 25.1 |
| Earnings yield | 2.2% |
| TTM EPS | ₹54.81 |
| TTM net profit | ₹2,264 cr |
| Quarter revenue | ₹4,338 cr |
| Quarter net profit | ₹711 cr |
| Net margin | 16.4% |
| Revenue growth (YoY) | +17.3% |
| Profit growth (YoY) | +48.9% |
| Return on equity | 16.2% |
| ROCE | 17.9% |
| Debt / equity | 0.31 |
| Current ratio | 1.37 |
| Free cash flow | ₹1,409 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹94.8 cr |

## Questions

### What is the P/E ratio of Mankind Pharma Limited?

Mankind Pharma Limited's trailing P/E is 45.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 21 May 2025 its P/E has ranged 39.2–56.5.

### What were Mankind Pharma Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Mankind Pharma Limited reported revenue of ₹4,338 cr and net profit of ₹711 cr (consolidated), filed with the exchange on 26 Oct 2026.

### What is Mankind Pharma Limited's ROE?

Return on equity is 16.2% based on the balance sheet dated 30 Sept 2026.

### Does Mankind Pharma Limited have debt?

Debt-to-equity is 0.31 on the balance sheet dated 30 Sept 2026.

### What is MANKIND's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, MANKIND traded between ₹1,909.70 and ₹2,642.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/MANKIND

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._